Basic Information
| LncRNA/CircRNA Name | DSCAM-AS1 |
| Synonyms | DSCAM-AS1, M41 |
| Region | GRCh38_21:40383083-40385358 |
| Ensemble | ENSG00000235123 |
| Refseq | NR_038896 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | Tamoxifen | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | breast cancer |
| ICD-0-3 | C50 |
| Methods | qPCR, Luciferase reporter assay, other |
| Sample | breast cancer tissues and cell lines (MCF7, T47D, SK-BR-3, and MDA-MB-31) |
| Expression Pattern | up-regulated |
| Function Description | LncRNA DSCAM-AS1 and EPS8 were significantly upregulated, whereas miR-137 was downregulated in TR tissues. DSCAM-AS1 could promote the Tamoxifen resistance of breast cancer, and it was negatively correlated with miR-137, whereas positively correlated with the expression of EPS8 in TR breast cancer tissues. Furthermore, miR-137 could inhibit tumor development and arrest cell cycle at the G0/G1 phase by targeting the 3'-UTR of EPS8. DSCAM-AS1 targeted miR-137 and EPS8 to promote propagation of TR breast cancer cells and inhibit cell apoptosis. |
| Pubmed ID | 30203615 |
| Year | 2019 |
| Title | LncRNA DSCAM-AS1 Acts as a Sponge of miR-137 to Enhance Tamoxifen Resistance in Breast Cancer |
External Links
| Links for DSCAM-AS1 | GenBank HGNC NONCODE |
| Links for breast cancer | OMIM COSMIC |